Latest news with #HCM
Yahoo
13 hours ago
- Business
- Yahoo
How Is Workday's Stock Performance Compared to Other Tech-Software Stocks?
Pleasanton, California-based Workday, Inc. (WDAY) is a leading cloud-based provider of enterprise software for human capital management (HCM), financial management, adaptive planning, spend management, and analytics. Valued at a market cap of $63.2 billion, the company delivers real-time operational insights and seamless workflows for HR and finance teams. Companies worth $10 billion or more are typically classified as 'large-cap stocks,' and WDAY fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the software - application industry. The company's specialty lies in delivering AI and machine learning-powered solutions that automate workflows, predict workforce needs, and optimize financial operations. Its strong presence among large enterprises, including over 60% of the Fortune 500, underscores its market leadership and its subscription-based SaaS model ensures stable, recurring revenue and high customer retention. 2 Outstanding Stocks Under $50 to Buy and Hold Now 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. This tech company has slipped 19.4% from its 52-week high of $294, reached on Dec. 9, 2024. Moreover, shares of WDAY have declined 6% over the past three months, considerably underperforming the iShares Expanded Tech-Software Sector ETF's (IGV) 15.9% uptick during the same time frame. In the longer term, Workday has gained 14.1% over the past 52 weeks, lagging behind IGV's 26.2% rise over the same time frame. Moreover, on a YTD basis, shares of WDAY are down 8.2%, compared to IGV's 6% return. To confirm its bearish trend, WDAY has been trading below its 200-day moving average since late May, and has recently started trading below its 50-day moving average. On May 22, WDAY released its Q1 results. The company's revenue improved 12.6% year-over-year to $2.2 billion and marginally exceeded the consensus estimates. Moreover, its adjusted operating margin expanded by a solid 430 basis points, driving a 28.2% annual increase in its adjusted EPS to $2.23. The bottom-line figure also came in well above Wall Street estimates. However, despite delivering a better-than-expected performance, its shares crashed 12.5% in the subsequent trading session. The sharp decline was not driven by company-specific factors but rather by broader market concerns. Trade tensions escalated after President Trump threatened a 25% tariff on Apple Inc. (AAPL) if iPhones were not produced in the U.S., dragging down Apple and other tech stocks including WDAY. The pressure intensified after Trump also warned of a 50% tariff on goods imported from the European Union since Jun. 1. Workday has slightly lagged behind its rival, Dayforce Inc's (DAY) 14.4% gain over the past 52 weeks. However, it has outpaced DAY's 22.6% decline on a YTD basis. Despite WDAY's recent underperformance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of "Moderate Buy' from the 37 analysts covering it, and the mean price target of $297.18 suggests a 25.5% premium to its current price levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
a day ago
- General
- Time of India
US experts to join ONGC efforts to control Assam gas well blowout in Sivasagar
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Guwahati: ONGC stated that an international team of well control experts has been mobilised from the United States of America and is expected to reach the site by the evening of June 20 to augment the response with specialised expertise as control the gas blowout at well RDS 147 A at Barichuk Bhatipara in Sivsagar and Natural Gas Corporation Limited (ONGC) continues to make concerted efforts to control the gas discharge from Well RDS#147A in Assam. Multiple junk shot operations using different combinations of materials and pressure ranges have been international team of well control experts has been mobilised from the United States of America and is expected to reach the site by the evening of 20 June 2025, to augment the response with specialised has initiated the development of an alternate route to facilitate movement of safe and efficient movement in and out of the well site. Further, bunk houses and non-essential equipment are also being removed from the blanketing operations are being maintained round-the-clock as a key safety measure. Preparations for the next phase of well control, including dynamic well killing strategies , are progressing stated, 'Ambient air quality monitoring in and around the well site is being conducted continuously. All parameters, including Particulate Matter (PM) levels and gas concentration, remain well within permissible is continuously supporting the affected families with the help of the district remains fully committed to ensuring the safety of the local community and the environment, and is working in close coordination with national and international experts to resolve the situation at the earliest.'Assam chief minister Himanta Biswa Sarma had a meeting with chairman of ONGC .The CMO official handle stated in X, 'HCM @himantabiswa met @ChairmanONGC Arun Kumar Singh at Lok Sewa Bhawan, Dispur, to review the well control operations at RDS#147A in Rudrasagar, Sivasagar. Terming the gas leak a matter of serious concern, HCM affirmed the Assam Government's commitment to ensuring the situation is swiftly brought under control and assured full support to ONGC in safeguarding public and environmental safety .'
Yahoo
3 days ago
- Business
- Yahoo
2025 Hypertrophic Cardiomyopathy (HCM) Market View: Analyze 34 Molecules in Development and Discover Trends in Clinical Trials, M&A Deals, and Innovative Therapies
Explore the future of Hypertrophic Cardiomyopathy Therapeutics with our comprehensive report. Anticipate over 2M cases in 16 countries by 2024. A shaping global markets. Key insights await! Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Hypertrophic Cardiomyopathy (HCM): Market View" report has been added to report offers a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy (HCM) Therapeutics. In 2024, over two million diagnosed prevalent cases are projected across 16 countries included in the epidemiology forecast. HCM management has traditionally depended on generic beta-blockers and calcium channel blockers for symptom relief. Currently, there are 34 molecules in development, including two in pre-registration, two in Phase III, and five in Phase II. Over the past decade, the U.S. led clinical trial activity with nearly 281 trial sites. In terms of deal activity, North America saw a balanced distribution of mergers and acquisitions, while Europe had an even split between acquisitions and asset transactions. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Hypertrophic Cardiomyopathy Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hypertrophic Cardiomyopathy Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface1.1 Contents1.2 Report Scope1.3 List of Tables and Figures1.4 Abbreviations2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market Catalysts11 Appendix11.1 Methodology11.2 Methodology - Sales Forecast11.3 Methodology - Pricing and Reimbursement11.4 Methodology - PTSR and LoA AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
12-06-2025
- Health
- Associated Press
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal
Yahoo
12-06-2025
- Health
- Yahoo
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. "Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease," said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. "It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care." FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. "Veterinarians have long-needed options beyond palliative care when it comes to feline HCM," said Dr. Joshua Stern, DVM, PhD, DACVIM. "With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception." Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
